Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2007-11-27
2011-12-27
Gibbs, Terra Cotta (Department: 1635)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C536S023100, C536S024300, C536S024330, C536S024500
Reexamination Certificate
active
08084437
ABSTRACT:
Disclosed herein are antisense compounds and methods for decreasing LDL-C in an individual having elevated LDL-C. Additionally disclosed are antisense compounds and methods for treating hypercholesterolemia, or alternatively for treating or preventing atherosclerosis. Further disclosed are antisense compounds and methods for decreasing coronary heart disease risk. Such methods include administering to an individual in need of treatment an antisense compound targeted to a PCSK9 nucleic acid. The antisense compounds administered include gapmer antisense oligonucleotides.
REFERENCES:
patent: 4981957 (1991-01-01), Lebleu et al.
patent: 5023243 (1991-06-01), Tullis
patent: 5118800 (1992-06-01), Smith et al.
patent: 5319080 (1994-06-01), Leumann
patent: 5359044 (1994-10-01), Cook et al.
patent: 5393878 (1995-02-01), Leumann
patent: 5446137 (1995-08-01), Maag et al.
patent: 5457187 (1995-10-01), Gmeiner et al.
patent: 5466786 (1995-11-01), Buhr et al.
patent: 5514785 (1996-05-01), Van Ness et al.
patent: 5519134 (1996-05-01), Acevedo et al.
patent: 5567811 (1996-10-01), Misiura et al.
patent: 5576427 (1996-11-01), Cook et al.
patent: 5591722 (1997-01-01), Montgomery et al.
patent: 5597909 (1997-01-01), Urdea et al.
patent: 5610300 (1997-03-01), Altmann et al.
patent: 5625050 (1997-04-01), Beaton et al.
patent: 5627053 (1997-05-01), Usman et al.
patent: 5633360 (1997-05-01), Bischofberger et al.
patent: 5639873 (1997-06-01), Barascut et al.
patent: 5646265 (1997-07-01), McGee
patent: 5652355 (1997-07-01), Metelev et al.
patent: 5658873 (1997-08-01), Bertsch-Frank et al.
patent: 5663312 (1997-09-01), Chaturvedula
patent: 5670633 (1997-09-01), Cook et al.
patent: 5677437 (1997-10-01), Teng et al.
patent: 5677439 (1997-10-01), Weis et al.
patent: 5681941 (1997-10-01), Cook et al.
patent: 5700920 (1997-12-01), Altmann et al.
patent: 5792747 (1998-08-01), Schally et al.
patent: 5801154 (1998-09-01), Baracchini et al.
patent: 5830653 (1998-11-01), Froehler et al.
patent: 6043060 (2000-03-01), Imanishi
patent: 6268490 (2001-07-01), Imanishi et al.
patent: 6426220 (2002-07-01), Bennett et al.
patent: 6525191 (2003-02-01), Ramasamy
patent: 6531584 (2003-03-01), Cook et al.
patent: 6582908 (2003-06-01), Fodor et al.
patent: 6600032 (2003-07-01), Manoharan et al.
patent: 6670461 (2003-12-01), Wengel et al.
patent: 6770748 (2004-08-01), Imanishi et al.
patent: 6794499 (2004-09-01), Wengel et al.
patent: 7034133 (2006-04-01), Wengel et al.
patent: 7053207 (2006-05-01), Wengel
patent: 7084125 (2006-08-01), Wengel
patent: 7217805 (2007-05-01), Imanishi et al.
patent: 7314923 (2008-01-01), Kaneko et al.
patent: 7399845 (2008-07-01), Seth et al.
patent: 7407943 (2008-08-01), Crooke et al.
patent: 7427672 (2008-09-01), Imanishi et al.
patent: 7511131 (2009-03-01), Crooke et al.
patent: 7605251 (2009-10-01), Tan et al.
patent: 7655785 (2010-02-01), Bentwich
patent: 7846706 (2010-12-01), Mintier et al.
patent: 2001/0053519 (2001-12-01), Fodor et al.
patent: 2003/0082807 (2003-05-01), Wengel
patent: 2003/0087230 (2003-05-01), Wengel
patent: 2003/0105309 (2003-06-01), Imanishi et al.
patent: 2003/0199467 (2003-10-01), Roberts et al.
patent: 2003/0224377 (2003-12-01), Wengel et al.
patent: 2003/0228597 (2003-12-01), Cowsert et al.
patent: 2004/0014959 (2004-01-01), Sorensen et al.
patent: 2004/0096848 (2004-05-01), Thrue et al.
patent: 2004/0143114 (2004-07-01), Imanishi et al.
patent: 2004/0171570 (2004-09-01), Allerson et al.
patent: 2004/0192918 (2004-09-01), Imanishi et al.
patent: 2004/0219565 (2004-11-01), Kauppinen et al.
patent: 2006/0128646 (2006-06-01), Christensen et al.
patent: 2007/0049542 (2007-03-01), Geller et al.
patent: 2008/0306015 (2008-12-01), Khvorova et al.
patent: 2009/0318536 (2009-12-01), Freier et al.
patent: 2010/0105134 (2010-04-01), Quay et al.
patent: 2007-215537 (2007-08-01), None
patent: WO 94/01093 (1994-08-01), None
patent: WO 94/22890 (1994-10-01), None
patent: WO 98/39352 (1998-09-01), None
patent: WO 99/14226 (1999-03-01), None
patent: WO 02/36743 (2002-05-01), None
patent: WO 03/011887 (2003-02-01), None
patent: 2004/097047 (2004-11-01), None
patent: WO 2005/012372 (2005-02-01), None
patent: WO 2005/121371 (2005-12-01), None
patent: 2006/126040 (2006-11-01), None
patent: WO 2007/090071 (2007-08-01), None
patent: WO 2007/131237 (2007-11-01), None
patent: 2008/011431 (2008-01-01), None
patent: 2008/043561 (2008-04-01), None
patent: WO 2008/043753 (2008-04-01), None
patent: WO 2008/066776 (2008-06-01), None
patent: 2008/109472 (2008-09-01), None
patent: WO 2009/148605 (2009-12-01), None
Alan D. Attie, “The Mystery of PCSK9,” Arterioscler. Thromb. Vasc. Biol., 2004, pp. 1337-1339, vol. 24.
Mark J. Graham et al., “Antisense Inhibition of Proprotein Convertase Subtilisin/Kexin Type 9 Reduces Serum LDL in Hyperlipidemic Mice,” J. Lipid Research, Jan. 22, 2007, pp. 763-767, vol. 48.
Florent Lalanne et al., “Wild-Type PCSK9 Inhibits LDL Clearance But Does Not Affect ApoB-Containing Lipoprotein Production in Mouse and Cultured Cells,” Journal of Lipid Research, 2005, pp. 1312-1319, vol. 46.
Gilles Lambert et al., “PCSK9: un nouveau gene implique dans l'hypercholesterolemie familiale”, Medecine/Science, Dec. 2004, pp. 1068-1070, vol. 20, No. 12.
Shirya Rashid et al., “Decreased Plasma Cholesterol and Hypersensitivity to Statins in Mice Lacking Pcsk9,” Proc. Nat'l Acad. Sci., Apr. 12, 2005, pp. 5374-5379, vol. 102, No. 15.
International Search Report issued on Jul. 28, 2008 for International PCT Application PCT/US2007/024369 filed Nov. 27, 2007.
Abifadel et al., “Mutations in PCSK9 cause autosomal dominant hypercholesterolemia” Nat. Genet. (2003) 34:154-156.
Graham et al., “Pharmacological Inhibition of PCSK9 in Hyperlipidemic Mice Significantly Reduces Serum LDL-C While Increasing Hepatic Low-Density Lipoprotein Receptor Protein Abundance” Arterioscler Thromb. Vasc. Biol. (2007) 27(6): p. E36.
Lambert et al., “PCSK9: un nouveau gene implique dans l'hypercholesterolemia familiale” M/S Medicine Sciences, Scoiete des Periodiques Flammarion, Paris France (2004) 20(12):1068-1070 (in French).
Lazowski et al., “Short, 12 mer fluorescently labeled methylphosphonated oligonucleotides to isualize beta-actin mRNA in vivo,” J Physiol Pharmacol. Dec. 2003;54(4):611-623, available at http://jpp.krakow.pl/journal/archive/1203/articles/12—article.html.
Maxwell et al., “Proprotein convertase subtilisin kexin 9: the third locus implicated in autosomal dominant hypercholesterolemia” Current Opinion in Lipidology (2005) 16(2):167-172.
Rashid et al., “Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9” Proc. Natl. Acad. Sci. U.S.A. (2005) 102(15):5374-5379.
Extended European Search Report for Application No. EP 07811874.2 dated Mar. 30, 2009.
International Search Report for Application No. PCT/US2007/068404 dated Mar. 13, 2008.
Branch et al., “A good antisense molecule is hard to find,” TIBS (1998) 23:45-50.
Chin “On the Preparation and Utilization of Isolated and Purified Oligonucleotides” Document purportedly located on a CD-ROM and contributed to the public collection of the Katherine R. Everett Law Library of the University of North Carolina on Mar. 14, 2002.
Crooke et al., “Basic Principles of Antisense Therapeutics” Antisense Research and Application (1998) Chapter 1:1-50.
Reynolds et al., “Rational siRNA design for RNA interference” Nature Biotechnology (2004) 22(3)326-330.
Sanghvi et al., “Heterocyclic Base Modifications in Nucleic Acids and Their Applications in Antisense Oligonucleotides” Antisense Research and Applications (1993) pp. 273-288.
Bellikova et al., “Synthesis of ribonucleosides and diribonucleoside phosphates containing 2-chloroethylamine and nitrogen mustard residues.” Tetrahedron Lett. (1967) 37:3557-3562.
Berger et al., “Universal bases for hybridization, replication and chain termination”
Bhanot Sanjay
Crooke Rosanne M.
Freier Susan M.
Graham Mark J.
Lemonidis Kristina M.
Drinker Biddle & Reath LLP
Gibbs Terra Cotta
Isis Pharmaceuticals , Inc.
LandOfFree
Methods for treating hypercholesterolemia does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for treating hypercholesterolemia, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for treating hypercholesterolemia will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4262954